Vupanorsen靶向ANGPTL3降低糖尿病合并肝脂肪变及高甘油三酯血症患者的甘油三酯和致动脉粥样硬化脂蛋白
这项2期双盲安慰剂对照剂量探索研究纳入105例空腹甘油三酯>150 mg/dL(>1.7 mmol/L)的2型糖尿病合并肝脂肪变患者,皮下注射vupanorsen 40或80 mg每4周一次或20 mg每周一次治疗6个月。与安慰剂相比,vupanorsen显著降低甘油三酯和ANGPTL3,80 mg每4周组还降低载脂蛋白C-III、残粒胆固醇、总胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B,但血糖指标和肝脏脂肪分数无改善。
要点
- vupanorsen选择性抑制ANGPTL3合成,显著降低甘油三酯和致动脉粥样硬化脂蛋白。
- 80 mg每4周组降低甘油三酯53%、ANGPTL3 59%、载脂蛋白C-III 58%、残粒胆固醇38%。
- 血糖参数和肝脏脂肪分数无改善,注射部位反应为最常见不良事件且多轻微。
核心结论
- Vupanorsen产生有利的脂质/脂蛋白谱,为降低残余心血管风险提供潜在策略。
研究设计与样本
- 双盲、安慰剂对照、剂量探索的2期研究,纳入105例空腹甘油三酯>150 mg/dL(>1.7 mmol/L)、2型糖尿病合并肝脂肪变患者。
- 患者随机接受vupanorsen 40或80 mg每4周一次、20 mg每周一次或安慰剂皮下注射治疗6个月。
- 主要疗效终点为6个月时空腹甘油三酯较基线的百分比变化。
主要发现
- 基线甘油三酯中位数为2.84 mmol/L(252 mg/dL)。
- 40 mg每4周组、80 mg每4周组和20 mg每周组甘油三酯分别降低36%、53%、47%,ANGPTL3分别降低41%、59%、56%;安慰剂组甘油三酯降低16%、ANGPTL3升高8%。
- 与安慰剂相比,vupanorsen 80 mg每4周组降低载脂蛋白C-III 58%、残粒胆固醇38%、总胆固醇19%、非高密度脂蛋白胆固醇18%、高密度脂蛋白胆固醇24%、载脂蛋白B 9%。
- 血糖参数和肝脏脂肪分数无改善。
- 血小板计数无临床显著变化,最常见不良事件为注射部位反应且多轻微。
临床怎么用
- 对于2型糖尿病合并肝脂肪变及高甘油三酯血症患者,vupanorsen可改善致动脉粥样硬化脂质谱,但未改善血糖和肝脏脂肪。
- 治疗期间需关注注射部位反应,血小板计数未见临床显著变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism and reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits angiopoietin-like 3 (ANGPTL3) protein synthesis. METHODS AND RESULTS: This was a double-blind, placebo-controlled, dose-ranging, Phase 2 study. Patients (N =105) with fasting triglycerides >150 mg/dL (>1.7 mmol/L), type 2 diabetes, and hepatic steatosis were treated for 6 months with 40 or 80 mg every 4 weeks (Q4W), or 20 mg every week (QW) of vupanorsen, or placebo given subcutaneously. The primary efficacy endpoint was per cent change in fasting triglycerides from baseline at 6 months. Median baseline triglycerides were 2.84 mmol/L (252 mg/dL). Significant reductions in triglycerides of 36%, 53%, 47%, and in ANGPTL3 of 41%, 59%, 56%, were observed in the 40 mg Q4W, 80 mg Q4W, and 20 mg QW groups, respectively, compared with 16% reduction in triglycerides and 8% increase in ANGPTL3 in placebo. Compared with placebo, vupanorsen 80 mg Q4W reduced apolipoprotein C-III (58%), remnant cholesterol (38%), total cholesterol (19%), non-high-density lipoprotein cholesterol (HDL-C; 18%), HDL-C (24%), and apolipoprotein B (9%). There was no improvement in glycaemic parameters, or hepatic fat fraction. Treatment with vupanorsen was not associated with clinically significant changes in platelet counts, and the most common adverse events were those at the injection site, which were generally mild. CONCLUSION: Vupanorsen results in a favourable lipid/lipoprotein profile and provides a potential strategy for residual cardiovascular risk reduction.
引用
- Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020. PMID: 32860031. doi:10.1093/eurheartj/ehaa689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。